MannKind wins FDA approval for Furoscix ReadyFlow autoinjector to treat edema in adults with heart failure or CKD

Reuters2026/07/24 17:35

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MannKind won FDA clearance for Furoscix ReadyFlow, an at-home autoinjector of subcutaneous furosemide for edema in adults with HF or CKD.
Product launch targeted by end-August 2026, cutting administration time to under 10 seconds from about five hours for the on-body infusor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MannKind wins FDA approval for Furoscix ReadyFlow autoinjector to treat edema in adults with heart failure or CKD

You may also like

Crypto prices